All the news Showing 10 of 119 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/ledipasvir/ribavirin cures 100% of genotype 1 hepatitis C patients Liz Highleyman / 05 March 2013 An interferon-free regimen containing sofosbuvir (formerly GS-7997), ledipasvir (formerly GS-5885) and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive hepatitis C patients and prior interferon non-responders, according ... Support improves hepatitis C treatment completion and response rates among drug users Michael Carter / 02 January 2013 Hepatitis C treatment completion and response rates among injecting drug users are similar to those seen in general patient populations, the findings of a meta-analysis published in the online edition of Clinical Infectious ... Adherence to hepatitis C treatment: unravelling the complexities Rob Camp / 13 December 2012 Successful adherence to hepatitis C treatment may require physicians and care teams to address a wide range of factors, according to research from the United States and Germany presented at The Liver Meeting ... Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring Liz Highleyman / 05 December 2012 Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivo), researchers reported ... Telaprevir twice-daily works as well as every eight hours, safe for hepatitis C patients with cirrhosis Liz Highleyman / 23 November 2012 The hepatitis C protease inhibitor telaprevir (Incivo or Incivek) taken twice daily with pegylated interferon plus ribavirin is as likely to produce sustained virological suppression as the approved three-times-daily schedule, with similar safety ... Which patients should be prioritised for new hepatitis C treatments? Rob Camp / 23 November 2012 Younger patients with advanced liver disease caused by hepatitis C should be prioritised for treatment with newly licensed directly acting antivirals to achieve the biggest reductions in ill health and hospitalisation, according to ... Low viral load in hepatitis C treatment: Is a third drug necessary? Rob Camp / 23 November 2012 When resources for hepatitis C treatment with new directly acting antivirals are limited, findings from the United States suggest that previously untreated people with low viral loads may stand a good chance ... Antiviral treatment reduces risk of liver cancer in people with hepatitis C-related cirrhosis and fibrosis Michael Carter / 29 October 2012 Antiviral treatment reduces the risk of hepatocellular carcinoma (HCC) in people with hepatitis C-related fibrosis or cirrhosis, according to the results of a meta-analysis published in British Medical Journal Open. The risk was ... Vitamin D deficiency associated with a poorer response to HCV treatment in HIV/HCV-co-infected patients Michael Carter / 11 October 2012 Vitamin D deficiency is associated with a poorer response to hepatitis C therapy in people who are co-infected with HIV and hepatitis C, investigators report in the online edition of AIDS. Austrian ... Higher levels of adherence to hepatitis C therapy improve treatment outcomes in people with hepatitis C and HIV Michael Carter / 03 October 2012 Higher levels of adherence to pegylated interferon and ribavirin are associated with better hepatitis C treatment responses in people with HIV and hepatitis C co-infection, US investigators report in AIDS and Behavior. Adherence ... ← Prev1...7891011...12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive